While the use of screening tests prevention of colorectal cancer or detection and at an earlier stage is recommended, only 59% of men and women 50 years of age and older receive colorectal cancer screening according to published guidelines. Less than 40% of these cases are diagnosed at a local stage when treatment has a higher success rate. The benefits of early detection are documented in the medical literature. One study showed that colonic polypectomy through colonoscopy reduced colon cancer mortality by 53% (3). In comparison to whites, all other racial and ethnic groups are less likely to be

diagnosed with colorectal cancer at an early stage when treatment is more successful. Inhibitors,research,lifescience,medical Whether this discrepancy is due to true difference between these groups or is secondary to lack of access of care remains undetermined. Inhibitors,research,lifescience,medical Epidemiological studies that assess this discrepancy

are crucial to determining the true nature of this racial disparity. According to the U.S. Census Bureau, Hispanics Inhibitors,research,lifescience,medical currently comprise 17% of the United States population at 53 million, and is projected to grow to 31% of the U.S. population by 2060 to an estimated 128.8 million people (4). In the US, Hispanics are the largest and fastest growing minority group. In the total Hispanic population, the TGF-beta inhibitor incidence of colorectal cancer is 46.9 per 100,000 with a mortality of 15.3 per 100,000 (1). Aspirin and statins may both reduce the incidence of colorectal cancer (5). Although data on the inverse association of daily aspirin and statin therapy exists in white and Inhibitors,research,lifescience,medical black patients, scarce data exists on their effect on the incidence of CRA in the Hispanic patient population. In this study we assessed whether reported use of these medications was associated with the incidence of CRA in our multi-racial hospital. Methods Patients Following Institutional Review Board (IRB) approval at Nassau University Medical Center, a 530-bed tertiary care teaching hospital

in East Meadow, Inhibitors,research,lifescience,medical New York, a retrospective chart review was performed between July 1, 2009 and March 21, 2011. We established a database of 1,843 patients undergoing screening or diagnostic colonoscopy. Only patients with listed tuclazepam medications were used for analysis. Patients with colon cancer, inflammatory bowel disease, or incomplete colonoscopies were excluded from this study. A total of 1,495 patients were included in the analysis on statin use, 1,038 patients were included in the analysis on aspirin use and 672 patients were included in the analysis of use of both statin and aspirin. Data were collected on patient demographics and potential risk factors for adenoma including age, sex, race, body mass index (BMI), diabetes, hypertension, smoking, alcohol, and family history of colorectal cancer along with aspirin and/or statin use.